home about mch acc help news cont

Dr. Theodore B. Moore, M.D.

Dr.Moore is Chief of the Division of Pediatric Hematology and Oncology at Mattel Children’s Hospital UCLA, serving concurrently as Clinical Director of the Division. He is also the Director of the Pediatric Blood and Marrow Transplant Program and the UCLA Site Director for the Glaser Pediatric Research Network. He is an Associate Professor of Pediatrics in the UCLA David Geffen School of Medicine.

Dr. Moore received his Board Certification in Pediatrics in 1992 and was re-certified in 2001. He is also Board Certified in Pediatric Hematology and Oncology. He trained in Pediatric Hematology/Oncology at UCLA from 1992-1995, serving as a Clinical Instructor from 1994-thru 1996. He then took the position of Director of Pediatric Stem Cell Transplant at the Oregon Health and Science University in Portland, Oregon building the Pediatric Hematopoietic Stem Cell Transplant program there from its infancy.

He returned to UCLA joining the UCLA School of Medicine faculty in 2001 with his current appointment in the Division of Pediatric Hematology/Oncology in the Department of Pediatrics. He is active in Clinical Research serving as the UCLA Principal Investigator for the Children's Oncology Group, the Pediatric Blood and Marrow Transplant Consortium, the Pediatric Cancer Research Foundation Consortium and UCLA Site Director for the Glaser Pediatric Research Network.

Dr. Moore's research focuses on pediatric hematopoietic stem cell transplantation, specifically stem cell sources and infections in the immunocompromised host. He and his colleagues also are working with acute leukemias and leukemiogenesis, as well as rare pediatric tumors and new drug development.

Selected Cancer-Related Publications:
Shankar DB, Li J, Tapang P, McCall JO, Pease LJ, Dai Y, Wei RQ, Albert DH, Bouska JJ, Osterling DJ, Guo J, Marcotte PA, Johnson EF, Soni N, Hartandi K, Michaelides MR, Davidsen SK, Priceman SJ, Chang JC, Rhodes K, Shah N, Moore TB, Sakamoto KM, Glaser KB, Owen McCall J. ABT-869 A multi-targeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood. 2007.

Parcells BW, Ikeda AK, Simms-Waldrip T, Moore TB, Sakamoto KM. FLT3 in Normal Hematopoiesis and Acute Myeloid Leukemia. Stem Cells. 2006.

Shankar DB, Cheng JC, Kinjo K, Federman N, Moore TB, Gill A, Rao NP, Landaw EM, Sakamoto KM. The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer Cell. 2005; 7(4): 351-62. Cheng JC, Moore TB, Sakamoto KM. RNA interference and human disease. Mol Genet Metab. 2003; 80(1-2): 121-8.

Dr. Gregory J. Del Zoppo, M.D., PhD. - full bio

Dr. Noah Federman, M.D. - full bio

Dr. Jacqueline Casillas, M.D. - full bio